Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Daclizumab in Patients With Chronic, Persistent Asthma

NCT00028288 is registered in ClinicalTrials.gov with Facet Biotech as lead sponsor.

NCT NCT00028288
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00028288 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Daclizumab in Patients With Chronic, Persistent Asthma
Lead sponsor
Facet Biotech
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2001
Completion date
December 31, 2003
Enrollment
120
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

asthma